By
AmyT on
October 29, 2008
I met Alexis at the recent BDI luncheon for women with Type 1 diabetes. She seemed bubbly and smart, and I felt an instant connection. When I discovered her job title was “Compliance Analyst,” I just had to hear more about that. Turns out it’s not quite what you think, but fascinating nevertheless.
A Guest Post by Alexis Pollack —
Compliance Analyst, Amylin Pharmaceuticals, Inc.
Type 1 diabetes for 15 years
Compliance. It’s not a…
Read more »
By
AmyT on
September 5, 2008
This morning Novo Nordisk announced that the FDA has scheduled an advisory committee meeting for its new Liraglutide once-daily GLP-1 drug, currently awaiting FDA approval. Believe it or not, this is huge news — with the potential to make or break a multi-billion-dollar diabetes drug category and set the tone for FDA safety proceedings in years to come.
What the FDA has done is to push off approval of Novo’s new Type 2 diabetes drug, over…
Read more »
I noticed a lot of chatter of late on diabetes forum sites about Symlin use. Some are still on the fence about trying this synthetic form of the human hormone Amylin, normally made by the beta cells, which helps level out post-meal glucose peaks. Others are just grateful that it’s now available in a convenient injection pen.
In early June, Amylin reported results of a study using Symlin with 112 patients with Type 2 diabetes,…
Read more »
